Nanologica AB (NICA)
XSTO 
XFRA Primary XSTO Summary
Nanologica AB (NICA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nanologica AB ever had a stock split?
Nanologica AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Andreas Bhagwani CEO | XSTO Exchange | SE0005454873 ISIN |
| Sweden Country | 72 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Nanologica AB (publ) is a Swedish biotechnology firm founded in 2004, specializing in the field of nanotechnology with a significant emphasis on life science applications. Operating globally, the company is engaged in the development, manufacturing, and selling of nanoporous silica particles. It functions through two main segments: Drug Development and Chromatography, showcasing its versatility and commitment to innovation within the pharmaceutical and biotech sectors. By leveraging its advanced technology, Nanologica aims to provide cutting-edge solutions that facilitate the analysis, purification, and development of drugs, particularly focusing on peptides and diabetes medications, as well as offering groundbreaking treatments for patients suffering from severe lung diseases through its nanoporous amorphous particles (NAP) platform technology.
Products and Services
- NLAB Saga
- SVEA (U)HPLC Analytical Columns
- Nanoporous Amorphous Particles (NAP)
A new generation silica product designed for preparative chromatography, NLAB Saga represents a significant advancement in the field. It offers high performance and efficiency in the purification process of pharmaceutical compounds, making it a valuable tool for drug development and manufacturing sectors.
These columns are essential for high-performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) applications, serving as critical components in the analysis of complex mixtures. SVEA analytical columns facilitate the precise separation and identification of substances, catering specifically to the rigorous demands of pharmaceutical analytics.
Nanologica’s NAP platform technology is at the forefront of inhalation therapy, offering new or improved treatments for patients with severe lung diseases. By leveraging the unique properties of nanoporous amorphous particles, this technology enables the delivery of drugs directly to the lungs, potentially transforming the therapeutic landscape for respiratory conditions.
